Registry following adults with lymphatic blood cancers across Germany
Records treatment, disease course and patient-reported outcomes in adults with lymphoma or leukemia.
Plain-language title generated from the registry record
Registry title: Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Key facts
- Where
- Freiburg im Breisgau, GermanySee the site
Where in Germany
- Praxis für Interdisziplinäre Hämatologie und OnkologieFreiburg im Breisgau, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- iOMEDICO AG
- Trial code
- NCT06043011
- Record updated
- 13 July 2026
- Original description
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.Read full original descriptionShow less
Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.
Inclusion: Age ≥ 18 years; Confirmed diagnosis of the respective NHL; If patient is alive: signed written informed consent; For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment; For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.
Exclusion: No systemic therapy for respective lymphoid malignancy.